Automated Insulin Delivery

The AJMC® Automated Insulin Delivery compendium is a comprehensive resource for clinical news and expert insights for this technology, which has revolutionized diabetes care.

Latest News
November 8th 2024

Enhancing Myasthenia Gravis Care With AI-Powered Telemedicine

December 20th 2022

Top 5 Most-Read Articles About Automated Insulin Delivery in 2022

December 6th 2022

Primary Care Clinicians Can Embrace CGM Implementation With Support, Study Finds

November 27th 2022

Study Identifies Factors Associated With Hypoglycemia Unawareness, Improvement

November 23rd 2022

Study Supports Funding for CGM to Improve Pediatric T1D Outcomes in New Zealand

A Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets

Read this review and Q&A with trial investigators of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in child and adult participants with type 1 diabetes.

Image of clinical brief about a tubeless, on-body automated insulin delivery system with customizable glycemic targets in child and adult participants with type 1 diabetes
Video Interviews
View All
August 12th 2022

Dr Viral Shah Addresses Gap in T1D Technology Uptake

November 19th 2021

Cynthia Rice Discusses JDRF's Progress in Making Automated Insulin Delivery More Available

November 14th 2021

Cynthia Rice: Automated Insulin Delivery Coverage Is Modernizing the Medicare Program

November 2nd 2021

Dr Robert Gabbay on Eliminating "Old-Fashioned" Finger Stick Rule

More News

Image of diabetes supplies
November 18th 2022

Do Automated Insulin Delivery Systems Have a Place in T2D Treatment?

Rose McNulty
Although automated insulin delivery systems have gained traction in type 1 diabetes, further research is needed to determine the feasibility of using such systems for patients with type 2 diabetes.
Image of glucose-testing materials
November 15th 2022

CGM Suggests Next-Gen Basal Insulin Analogs Lead to Similar Time-in-Range in T1D

Jared Kaltwasser
These second-generation basal insulin analogs, Gla-300 and IDeg-100, also had similar safety profiles, investigators found.
Image of glucose monitoring
November 9th 2022

CGM Can Be Used in the ICU to Monitor Patients With T2D

Jared Kaltwasser
A new report has found continuous glucose monitoring (CGM) may help reduce staff burden in the intensive care unit (ICU) by reducing the need for blood gas monitoring.
colorful graphic of lungs
October 24th 2022

CGM May Be Useful Diagnostic Tool for Diabetes in Cystic Fibrosis, but Data Scarce

Jared Kaltwasser
It is not yet clear what continuous glucose monitoring metrics should be used for a diabetes diagnosis in people with cystic fibrosis.
image of fingerstick in type 1 diabetes
October 18th 2022

Continuous Monitoring Outperforms Fingerstick Testing in Patients With T1D, High Glycated Hemoglobin

Jared Kaltwasser
The report found people using continuous monitoring systems spent more time in their target glucose ranges.
Task Force Calls for Prioritizing Safety, Privacy in AID Use; Seeks Harmony Among Regulators
October 10th 2022

Task Force Calls for Prioritizing Safety, Privacy in AID Use; Seeks Harmony Among Regulators

Mary Caffrey
Along with its position statement in Diabetologia, the group outlined recommendations that seek greater structure and consistency for automated insulin delivery (AID) manufacturers as they develop products for use by persons with type 1 and type 2 diabetes.
Bringing Greater Context to Precision Monitoring in Patients With Diabetes
October 6th 2022

Bringing Greater Context to Precision Monitoring in Patients With Diabetes

Pearl Steinzor
A new review article explores how precision monitoring of blood glucose can be informed by the connections among self-care behaviors, mental health, and glucose level maintenance.
Diabetes graphic
September 29th 2022

Diabetes Technology May Impact Patient Approach to Prevent Overnight Hypoglycemia

Jaime Rosenberg
Data showed that patients using diabetes technology incorporated different strategies to prevent nocturnal hypoglycemia vs patients who did not use such technology.
Image of an AID
September 16th 2022

Sustained Glucose Control Does Not Slow Decline of C-Peptide in Randomized T1D Study

Jaime Rosenberg
This randomized, multicenter study of children and adolescents with new-onset type 1 diabetes (T1D) investigated the effect on glucose control of a closed-loop system, using C-peptide levels to gauge response
picture of the word diabetes
September 12th 2022

CGM May Improve Glycemic Control in Patients With Diabetes and Cystic Fibrosis

Jaime Rosenberg
The review included data from 17 studies of over 400 patients using continuous glucose monitors (CGM).
Diabetes image
September 7th 2022

Advanced Hybrid Closed-Loop System Helps Achieve T1D Glucose Targets in New Trial

Jaime Rosenberg
The trial followed patients with type 1 diabetes (T1D) for 6 months, evaluating outcomes in patients struggling to achieve glucose targets with the conventional treatment.
Image of health care technology
August 27th 2022

DIY Automated Insulin Delivery Systems Bring Unique Challenges to HCPs

Jaime Rosenberg
Do-it-yourself (DIY) automated insulin delivery systems have gained rapid uptake, yielding self-reported improvements in glycemic control and quality of life for patients, but creating unique challenges for health care providers (HCPs).
picture of teenagers
August 15th 2022

Parents of Youth With T1D Generally Prefer Virtual Visit for CGM Initiation

Jaime Rosenberg
The interview-based study collected feedback from 16 parents of 15 youth recently diagnosed with type 1 diabetes, finding that the majority preferred a virtual continuous glucose monitoring (CGM) information initiation visit rather than an in-person visit.
Older man sleeping
August 11th 2022

Closed-Loop Insulin Delivery Has Glycemic Benefits During Sleep at Cost of Sleep Quality

Lindsey Mulrooney
Compared with sensor-augmented pump therapy, closed-loop insulin delivery increased glucose time in range and reduced hypoglycemia episodes but detracted from sleep quality.
a woman using a CGM
July 27th 2022

Use of Continuous Glucose Monitoring Devices Varies by Age for Patients With T1D

Lindsey Mulrooney
Probability of continuous glucose monitoring device use was highest for patients with type 1 diabetes (T1D) in middle adulthood, decreasing as older age increased.
hospital image
July 22nd 2022

CGM for Diabetes on the Rise in Italy, but Usage Is Still Lower Than Expected, Study Says

Allison Inserro
Children with type 1 diabetes had the highest rates of using continuous glucose monitoring and continuous subcutaneous insulin infusion in Italy, according to recent research, but economic barriers prevent widespread adoption.
omnipod.
July 21st 2022

Omnipod 5 May Improve Psychosocial Outcomes for Patients With T1D, Study Suggests

Lindsey Mulrooney
Patients with type 1 diabetes (T1D) who used the Omnipod 5 Automated Insulin Delivery (AID) System saw significant improvements in psychosocial outcomes, including diabetes distress and hypoglycemic confidence over a 3-month period.
Image of automated insulin delivery
July 6th 2022

Omnipod 5 Effective at Glycemic Control Across Spectrum of Insulin Needs

Maggie L. Shaw
Knowing that insulin requirements vary widely among persons who have type 1 diabetes, 3-month effectiveness of the Omnipod 5 Automated Insulin Delivery System was evaluated across 6 daily insulin doses.
Image of an AID system
June 29th 2022

Omnipod 5 T1D Glycemic Outcomes Continue to Improve Over the Longer Term

Maggie L. Shaw
Extended safety and effectiveness of the Omnipod 5 AID system were investigated in this 12-month extension of a previous 3-month study conducted among persons living with type 1 diabetes (T1D).
Image of diabetes technology
June 21st 2022

There Is More to Blame Than Tech for T1D Outcomes Disparities, Investigators Argue

Maggie L. Shaw
Investigators from the Pediatric Diabetes Center at Hassenfeld Children’s Hospital at NYU Langone investigated outcomes disparities as they related to diabetes technology use among youth living with type 1 diabetes (T1D).
Artificial Intelligence “Twin” Technology Improves Remission Rates for T2D
June 12th 2022

Artificial Intelligence “Twin” Technology Improves Remission Rates for T2D

Lindsey Mulrooney
A wearable device powered by artificial intelligence and the Internet of Things to create a "digital twin" reduced glycated hemoglobin and improved remission rates for patients with type 2 diabetes (T2D) through personalized care.
Image of a continuous glucos emonitor
June 9th 2022

CREATE Trial Data Add to Support of Open-Source AID Use in T1D

Maggie L. Shaw
Findings presented at the 82nd Scientific Sessions of the American Diabetes Association support the safety and efficacy of open-source automated insulin delivery (AID) systems among children and adults living with type 1 diabetes (T1D).
Image of an insulin pump
May 31st 2022

Fully Artificial Pancreas Produces Results Comparable With Hybrid Artificial Pancreas

Maggie L. Shaw
This new study from Canada compared outcomes in patients living with type 1 diabetes who used 2 closed-loop insulin delivery systems: a fully artificial pancreas that did not require meal input and a hybrid artificial pancreas that required carbohydrate counting.
Image of physician and young child
May 24th 2022

Emotional Improvement Seen Among T1D Patients Using CLC Systems

Maggie L. Shaw
The authors of this study evaluated outcomes among children aged 7 to 16 years, all living with type 1 diabetes (T1D), who attended a 3-day virtual education camp that focused on their use of a closed-loop control (CLC) system for insulin delivery.
Image of A1C data
May 20th 2022

Stronger Frameworks Needed to Implement CGM Use at Hospital Discharge

Maggie L. Shaw
Continuous glucose monitor (CGM) use as part of a telemedicine program in patients with type 2 diabetes transitioning out of a hospital setting and to a different diabetes therapy was evaluated in this new open-label study.
Image of an elderly couple
May 15th 2022

Superior T1D Control Seen With HCL Systems vs SAP Therapy in Older Adults

Maggie L. Shaw
Type 1 diabetes (T1D) can be especially difficult to manage in older adults, so this new multinational review compared the safety and effectiveness of a hybrid closed-loop (HCL) system and sensor-augmented pump (SAP) therapy.
Image of a continuous glucose monitor
May 11th 2022

HCL Systems Convey Superior Glucose Outcomes vs Other Diabetes Technologies

Maggie L. Shaw
This new study among a patient population living with type 1 diabetes compared their outcomes according to their type of insulin pump therapy: sensor-augmented pump, predictive low-glucose suspend, and hybrid closed-loop (HCL).
Image of clinical data
May 9th 2022

Study Incorporates CGM Data for Guideline, Treatment Development

Maggie L. Shaw
A new study incorporated use of readings from continuous glucose monitors (CGMs) to establish reference sensor glucose ranges among healthy nondiabetic children aged 1 to 6 years.
Image of a balance between medicine and paying
May 4th 2022

SES-Related Insulin Pump Uptake Disparities Seen in 2 Canadian Provinces

Maggie L. Shaw
Using socioeconomic status (SES) as their primary exposure, investigators from McGill University, University of Manitoba, Institut National de Santé Publique du Québec, and Laval University investigated reasons behind insulin pump uptake disparities in the Canadian provinces of Manitoba and Québec.
Omnipod 5
May 3rd 2022

Results of Omnipod 5 Type 2 Feasbility Study Presented at ATTD

Mary Caffrey
Patients with type 2 diabetes who used the Omnipod 5 had lower A1C after 8 weeks. Those who had been using multiple daily injections achieved the greatest benefits in reduced hypoglycemia and reduced insulin use.
123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo